How to Value a Functional Medicine Practice in 2026

Functional medicine is the highest-multiple primary care model I value, and it's not close. A well-run functional medicine practice with premium cash-pay pricing, real lab and supplement infrastructure, and a credentialed MD or DO at the top routinely trades between 3.0x and 5.0x SDE — and the outliers at the top end are approaching the multiples paid for dermatology and concierge primary care.

The reason is simple: functional medicine has solved the two problems that traditionally limit primary care valuations. It's cash-pay, so there's no insurance risk. And it generates 35-55% of revenue from ancillary lab and supplement sales, which behave more like a retail business than a clinical one. Put those two together and you have something that looks a lot more like a specialty retail practice than a standard medical clinic.

The Functional Medicine Valuation Range

• 2.5-3.0x SDE: Solo practitioner (MD, DO, NP, or ND practicing functional medicine), partial cash-pay, some supplement revenue but no real infrastructure, founder is the entire brand.
• 3.0-3.5x SDE: Established cash-pay practice with documented protocols, $150K+ in annual supplement revenue, specialty lab testing as a standard part of care.
• 3.5-4.5x SDE: Multi-provider practice with a clear program structure (6-month protocols, membership tiers), high-margin dispensary exceeding 35% of revenue, documented patient outcomes.
• 4.5-5.0x+ SDE / 6-8x EBITDA: Multi-location or specialty-focused (longevity, hormone optimization, autoimmune), MD or DO at the top, associate providers delivering the bulk of visits, recurring program revenue, $750K+ EBITDA.

The gap between a 3x and a 4.5x multiple on a practice generating $400K SDE is $600K of sale value. That's not a rounding error — it's the difference between a comfortable retirement and an exceptional one.

Premium Pricing as the Foundation

Functional medicine practices charge what traditional primary care can't. Initial consultations run $500-$1,500 for 90-120 minutes. Follow-ups are $250-$500. Full programs (6-month hormone optimization, 12-week gut restoration, 16-week autoimmune protocols) are typically priced $2,800-$8,500 per patient all-in, including labs and supplements.

The practices that sustain these prices have three things in common:

• An MD or DO at the top of the clinical hierarchy. Not because the clinical work is necessarily better, but because the pricing holds. Patients paying $6,000 out of pocket want to see "Dr." on the wall — specifically a medical doctor. Practices led by chiropractors or nutritionists typically can't sustain the same price points.
• A program structure, not a visit structure. Practices that sell 6-month programs have forward-booked revenue, higher per-patient lifetime value, and better outcomes (because patients are committed to the process). Practices that bill per visit look more like a premium concierge primary care practice and trade at lower multiples.
• Clear patient selection. The best-valued functional medicine practices turn away patients who aren't a fit — those looking for a single-visit answer, those who won't do the testing, those who can't commit to the protocol. This maintains pricing and outcomes.

When preparing for sale, document your average revenue per patient (ARPP) over 36 months, your program completion rate, and your cash collection velocity (time from patient commitment to cash in the door). Buyers underwriting a functional medicine practice are essentially underwriting whether the pricing model holds without the founder in the room — and clean ARPP data is the best evidence you can provide.

Lab Revenue: The Hidden Margin Engine

Specialty lab testing in functional medicine isn't incidental — it's often 20-30% of total revenue at a 40-60% markup. Understanding and documenting this line is where most sellers either leave money on the table or price themselves out of a deal.

A typical functional medicine new-patient workup might include:

• Comprehensive metabolic and CBC panels through a standard reference lab (LabCorp, Quest) — $85-$150 cost, $150-$300 charged.
• DUTCH hormone panel — $250 cost, $400-$550 charged.
• GI-MAP stool test — $260 cost, $425-$525 charged.
• Organic Acids Test (OAT) — $275 cost, $425-$525 charged.
• Food sensitivity panel — $220 cost, $350-$450 charged.
• Micronutrient testing (Spectracell, Genova) — $390 cost, $525-$650 charged.

A single new-patient workup can generate $2,000-$2,800 in lab revenue against $1,300-$1,600 in lab cost — $700-$1,200 of gross margin per new patient, on top of the consultation fee. A practice onboarding 12 new patients per month is generating $8,400-$14,400 monthly in lab margin, or $100K-$170K annually, before a single supplement is sold.

Buyers value this differently than clinical visit revenue. Lab revenue is higher margin, more scalable (a second provider doesn't dilute lab gross margin the way they dilute visit revenue), and tied to documented clinical protocols that transfer with the practice. Segregate lab revenue on your P&L and track it month-over-month.

Supplement Revenue: Recurring and Sticky

The supplement dispensary is the third leg of functional medicine economics, and it's the most durable. Patients on a 6-month hormone optimization protocol are buying $180-$350 of supplements per month, and they're buying them every month, and they're buying them from your dispensary because the protocol is built around specific brands and dosages.

A practice with 300 active protocol patients spending an average of $210/month in supplements is generating $63K/month, or $750K/year, of supplement revenue at roughly 40-45% gross margin. That's $300K-$340K of contribution flowing to SDE from a single ancillary line.

The valuation math is significant. Buyers apply the overall SDE multiple to supplement contribution, but the more important effect is that documented recurring supplement revenue reduces the buyer's perceived risk — which moves the multiple up. A practice that can show 18 months of supplement revenue stable at $50K+/month is a fundamentally different asset than one that can't.

The best platforms for documentation are Fullscript and Wellevate for online dispensaries (transaction data exports cleanly) and physical inventory tracked through a proper POS like Square for Retail for in-house dispensaries. Avoid hybrid models where supplement sales are partially tracked in one system and partially in another — it makes diligence painful and buyers will discount for the uncertainty.

The PE and Strategic Buyer Landscape

Functional medicine is starting to see real private equity interest, though nothing like the dental DSO wave yet. The active buyer categories are:

• Longevity platforms. Companies like Parsley Health, Forward, and a handful of VC-backed longevity clinics are acquiring or partnering with established practices to accelerate regional expansion. They pay up for practices with strong operational systems and scalable protocols — 6-9x EBITDA for platform-quality targets with $750K+ EBITDA.
• Integrative health holding companies. Groups rolling up multi-disciplinary wellness clinics (functional medicine + IV therapy + aesthetics + hormones) typically pay 4.5-6x EBITDA for bolt-ons with $400K+ EBITDA.
• Physician-led acquirers. Established functional medicine MDs expanding to a second or third location. Usually pay 3.5-4.5x SDE for well-run smaller practices.

Practices under $400K EBITDA are generally limited to the physician-buyer pool, which caps the multiple. If you're within 2-3 years of clearing the $500K EBITDA threshold, it's almost always worth waiting — the multiple expansion alone typically justifies the delay.

Provider Credentialing: MD/DO vs. NP vs. ND

This is uncomfortable to talk about but it matters in the valuation conversation. Practices led by an MD or DO trade at the highest multiples. Practices led by a nurse practitioner or physician assistant trade somewhat lower. Practices led by a naturopath or chiropractor practicing functional medicine trade lower still, primarily because the buyer pool is smaller and the insurance/regulatory risk is higher.

The gap isn't because the clinical work is different. It's because:

• MDs and DOs can maintain the highest price points without patient resistance.
• The buyer pool for an MD-led practice includes other MDs, PE platforms, and health systems. For an ND-led practice, it's almost exclusively other NDs.
• Prescriptive authority is cleaner for MD/DO practices in every state.
• Malpractice insurance and liability structure is more standardized.

If you're an MD or DO in a functional medicine practice, emphasize that credentialing in your offering materials. If you're an NP or PA, highlight your collaborative physician relationships and prescriptive authority documentation. If you're an ND or DC, focus the pitch on state licensing, scope documentation, and the strength of your clinical outcomes data.

What Kills Functional Medicine Value

Founder as the only brand. If patients come for you specifically — your book, your podcast, your Instagram — the practice is a media business with a clinic attached, and media businesses don't transfer. Buyers discount heavily.

Program revenue booked upfront with delivery spread over 6 months. Makes revenue recognition messy. Buyers normalize this during diligence and often surface deferred revenue liabilities that reduce the effective purchase price. Get your revenue recognition clean before going to market.

High patient acquisition cost. If you're spending $800-$1,500 per new patient acquired through paid advertising, buyers see an unsustainable marketing engine. Practices with organic patient flow through physician referrals, word of mouth, and content marketing trade at premium multiples.

Cash-tight during due diligence. Functional medicine practices often run on thin working capital because supplement inventory ties up cash. Clean up your balance sheet 6 months before sale — buyers don't want to solve an inventory financing problem during the deal.

How to Maximize Your Exit

Hit $500K EBITDA before you go to market. The multiple expansion from 3.5x to 5x that comes with crossing that threshold is worth more than another year of cash flow.

Hire a second provider 18-24 months before selling. Structure the onboarding so they take over at least 40% of new patient consultations. Prove the model works with a different face.

Separate your P&L by revenue category: clinical visits, labs, supplements, programs, ancillary services (IV, injections). Three years of clean segmented financials is the single most valuable diligence preparation you can do. See our SDE versus EBITDA guide for how buyers normalize these categories.

Document your protocols. A functional medicine practice with written clinical protocols, decision trees, and treatment pathways is a dramatically more valuable asset than one where the care model lives in the founder's head. Buyers pay for operational documentation because it reduces the integration risk they're underwriting. The 18-month pre-sale preparation timeline I recommend is especially important for functional medicine practices because there's more operational complexity to document than in a traditional primary care clinic.

The Bottom Line

Functional medicine is the rare healthcare segment where doing the right things operationally — building programs, documenting protocols, adding providers, segregating revenue lines — translates almost directly into multiple expansion. The difference between a 3x and a 5x exit on a $500K EBITDA practice is $1 million of sale value. That gap is entirely capturable through 18-24 months of deliberate preparation. The practices that plan for it get it. The practices that don't, leave it on the table.